Wegovy vs Zepbound: total cost of treatment, year 1 vs year 5

TLDR. A 5-year course of Wegovy through NovoCare cash-pay costs about $30,000. The same course of Zepbound through LillyDirect costs about $33,000. With PA-approved commercial insurance, both drop to roughly $1,500 to $3,000 over 5 years. With HSA dollars at a 30 percent marginal tax rate, the effective cost drops another 30 percent. Zepbound delivers more weight loss per dollar at the maximum dose; Wegovy delivers more weight loss per dollar at a sub-maximum dose. The cheapest legitimate path remains commercial insurance with PA approval, followed by HSA-paid manufacturer direct programs, followed by cash-pay compounded semaglutide. Here is the actual math.

The four pricing rails

In 2026, GLP-1 weight-loss medication reaches patients through four price rails:

1. Commercial insurance with PA approval: $25 to $150 per month copay after PA
2. Manufacturer direct cash-pay: NovoCare Wegovy at $199 to $499/month, LillyDirect Zepbound vials at $349 to $549/month
3. HSA or FSA payment of any of the above: reduces effective cost by your marginal tax rate
4. Compounded semaglutide: $99 to $250/month, branded only via compounding pharmacies (a different drug, see our compounded explainer)

This article focuses on the three FDA-approved branded paths (rails 1, 2 and 3). For the compounded comparison, see the article above.

The headline-trial efficacy you are buying

Quick reminder of what your dollars are buying, per the registration trials:

• Wegovy 2.4 mg semaglutide weekly: 14.9 percent mean body weight loss at 68 weeks (STEP-1, NEJM 2021)
• Zepbound 15 mg tirzepatide weekly: 22.5 percent mean body weight loss at 72 weeks (SURMOUNT-1, NEJM 2022)
• Zepbound 10 mg: 21.4 percent mean body weight loss
• Zepbound 5 mg: 16.0 percent mean body weight loss (roughly equal to Wegovy 2.4 mg)

The clinically relevant comparison is Wegovy 2.4 mg versus Zepbound 5 mg: roughly equal weight-loss outcomes. Zepbound at higher doses produces more weight loss. Wegovy does not have a higher-dose option to escalate to.

Year 1 cost: cash-pay through manufacturer direct

Year 1 cash-pay range: roughly $5,100 to $6,600 across the FDA-approved branded paths. The price differences within Wegovy and within Zepbound depend on which dose you stabilize at.

Year 1 cost: PA-approved commercial insurance

With prior authorization approved, copays at most large commercial plans are:

Add the manufacturer savings cards on top: Novo's Wegovy Savings Card can reduce commercial-insurance copay to as low as $0 for up to 13 months, with a $225/month cap. Lilly's Zepbound Savings Card can reduce copay to $25 for the first month and up to $150 off subsequent monthly fills, with a 12-month cap.

Year 1 cost with commercial insurance and PA approved: $300 to $1,800 typical range, depending on tier and savings-card use.

For the PA process itself, see our PA step-by-step. The PA itself doesn't cost the patient anything; it's a documentation submission by the prescriber.

Year 1 cost: HSA-paid manufacturer direct

Health Savings Accounts let you pay qualified medical expenses with pre-tax dollars. The effective cost reduction depends on your marginal tax rate:

Add state income tax savings (where applicable) and FICA savings if your contributions go through payroll. A patient in a 22 percent federal bracket plus 5 percent state tax saves about $1,617 per year on a $5,988 Wegovy bill, dropping the effective cost to $4,371.

HSA dollars do not stack with manufacturer savings cards, but they can pair with insurance copays: if your copay is $50/month, HSA-paying that copay gives you the same tax discount.

Three worked examples

Example A: Salaried professional, employer PPO, BMI 32, no diabetes

Maria, 38, BMI 32.1, hypertension on lisinopril. Employer is a self-insured PPO administered by Blue Cross Blue Shield. Formulary lists Wegovy at Tier 3 with PA required, Zepbound not covered. Maria has a Health Savings Account through her HDHP.

Her path:

1. Prescriber submits Wegovy PA citing BMI 32.1 and I10 hypertension. PA approved in 7 days.
2. Tier 3 copay is $125/month. Maria activates the Wegovy Savings Card, which brings copay to $0 for the first 13 fills, then $125/month with a $225/month savings cap.
3. Maria pays from her HSA, capturing 28 percent federal-plus-state tax savings.

Year 1 effective cost: roughly $200 (savings-card-covered fills 1-13). Year 2 effective cost: $1,080 (12 x $125 x 72 percent post-tax). Year 5 cumulative: about $4,500. Compared to cash-pay $30,000 for the same outcome.

Example B: Independent contractor, no insurance, BMI 28 with sleep apnea

James, 44, BMI 28.7, untreated obstructive sleep apnea confirmed by recent sleep study. No employer-sponsored insurance; pays for ACA marketplace bronze plan with $7,500 deductible and HSA-eligible status.

His path: bronze plan covers nothing toward GLP-1 until deductible is met. Cash-pay through NovoCare Wegovy is $499/month at the 1.7-2.4 mg maintenance dose, or $349-$549/month for Zepbound vials. James funds his HSA at the family-coverage max ($8,550 in 2026) and pays for Zepbound 5 mg vials at $549/month.

HSA-paid Zepbound 5 mg, 24 percent marginal tax rate: effective cost $417/month, $5,004/year. Year 5: $25,020. The bronze deductible is irrelevant because the GLP-1 is excluded from the formulary entirely for weight loss.

Example C: Retired, Medicare Part D, BMI 36, T2D and CVD history

Linda, 68, BMI 36.4, type 2 diabetes (A1c 7.8), prior myocardial infarction in 2022, on statin and metformin. Medicare Part D with a standard Part D plan.

Her path: Medicare Part D covers Ozempic and Mounjaro for T2D under standard PA. Linda's prescriber writes Mounjaro 5 mg titrating to 10 mg. Tier 3 copay on her Part D plan is $47/month. The $47 copay does not stack with the Mounjaro Savings Card because the card excludes government insurance.

Year 1: $564. Year 5: $2,820. For Linda's CVD history, her prescriber could also submit Wegovy under the 2024 CVD risk-reduction Medicare indication, which is similar in cost. Linda picks Mounjaro because tirzepatide outperforms semaglutide on glycemic and weight outcomes (SURPASS-2). See our Mounjaro vs Zepbound article.

Year 5 cost: the long-run math

Most patients stay on GLP-1 medication long-term. Stopping at goal weight produces regain (see our discontinuation article), so the cost question is not "one year" but "as long as I am on the drug."

The 5-year spread runs from about $1,500 (insurance Tier 2 plus savings card) to about $33,000 (Zepbound cash-pay all-in). The same molecule, the same outcome, a 22x price difference.

The Zepbound efficiency premium

The interesting cost-per-percent-weight-loss comparison:

• Wegovy 2.4 mg cash: $5,988/year for 14.9 percent loss = $402 per percent
• Zepbound 5 mg cash: roughly $4,200/year (lower titration dose stable) for 16.0 percent loss = $263 per percent
• Zepbound 15 mg cash: $6,588/year for 22.5 percent loss = $293 per percent

Zepbound at the 5 mg dose is the most cost-efficient FDA-approved cash-pay path. Most patients are titrated higher because higher doses produce more loss, but the per-percent cost climbs.

For a patient with a 15-percent weight-loss goal and no plan to go higher, Zepbound 5 mg is the cheapest brand path. For a patient who wants the maximum loss the class can deliver, Zepbound 15 mg gets you there.

What the math leaves out

Three real costs not in the tables above:

• Telehealth or prescriber visit fees. $40 to $200/month at most cash-pay telehealth programs, often included in the listed price. A PCP-prescribed path costs $0 to $50/visit incremental on top of the medication. See our primary-care vs telehealth comparison.
• Lab work. Baseline metabolic panel, A1c, lipid panel, sometimes thyroid: $100 to $300 if cash-pay, $0 to $50 if covered by insurance. Repeat annually.
• Side-effect management. Anti-nausea medication (ondansetron) is $5 to $20 per month if needed. Constipation management is dietary. Rare-but-real events like gallbladder issues can add hundreds in medical visits.

Add another $500 to $1,500/year for these incidentals across most paths.

Decision rules by patient situation

You have commercial insurance with explicit GLP-1 weight-loss coverage

Run PA on Wegovy first (more often covered), Zepbound second. Use the manufacturer savings card. Expect $25 to $150/month after PA. Year-5 cost likely $1,500 to $9,000.

You have commercial insurance without GLP-1 weight-loss coverage but with HSA

Pay the manufacturer direct program with HSA dollars. Pick Zepbound 5 mg if your goal is moderate weight loss; pick Wegovy 1.7 mg or Zepbound 10 mg+ if your goal is larger. Year-5 cost likely $18,000 to $23,000.

You are cash-pay with no insurance

The branded path is $26,000 to $33,000 over 5 years. The compounded semaglutide path is $6,000 to $15,000 over the same period. The clinical outcome is comparable for semaglutide; tirzepatide is harder to source compounded in 2026. See our compounded vs branded explainer for the regulatory and quality differences.

You are Medicare

Medicare does not cover Wegovy or Zepbound for weight loss. The exception: Wegovy for cardiovascular risk reduction in established CVD patients, covered under Part D as of 2024 after SELECT. For pure weight-loss indication on Medicare, cash-pay through NovoCare or LillyDirect is the only path. Year-5 cost: $26,000 to $33,000.

The fifth-year question

Patients often ask: do I need to stay on this drug forever?

The trial extension data (STEP-5, SURMOUNT-4, SELECT) is consistent: patients who continue maintain their loss; patients who stop regain. Reaching goal weight is not a stopping point in the disease model; it is a stable state that requires continued treatment, the same way blood-pressure medication does for hypertension.

A patient who stops at year 5 and regains to BMI 30 ends up worse-off (higher body fat percentage, lower lean mass, lower resting metabolic rate) than a patient who maintains. The economically rational long-term plan is staying on the lowest dose that holds the loss, which for some patients is a microdose at 0.25 to 0.5 mg semaglutide weekly. Generic semaglutide arriving in 2027 should drop maintenance costs another 50 to 70 percent. See our generic launch article.

FAQ

Do NovoCare and LillyDirect require insurance?

No. Both are explicitly cash-pay programs. NovoCare and LillyDirect do not bill insurance; you pay them directly. If you have insurance that covers the drug, do not use NovoCare or LillyDirect; use your insurance because the copay path is cheaper than the manufacturer direct cash price.

Can I use my HSA for compounded semaglutide?

Yes, when prescribed for a qualifying medical condition. The IRS does not distinguish between FDA-approved and compounded medications for HSA-eligible-expense purposes; both qualify as medical expenses when prescribed by a clinician. Keep the prescription and the pharmacy receipt for documentation.

Why is Zepbound vial cheaper than Zepbound pen?

LillyDirect launched the Zepbound vial in late 2024 at lower prices than the pen ($349 for the 2.5 mg starter vial versus $549 for the equivalent pen) to compete with compounded tirzepatide and to expand the cash-pay market. The vial requires drawing the dose into a syringe yourself; the pen handles dosing automatically. The medication is identical. See our injection-technique guide for the vial workflow.

Does the Wegovy Savings Card stack with insurance?

Yes, for commercial insurance only. The card brings the insured copay down further, often to $0 for the first 13 fills. The card does NOT work with Medicare, Medicaid, Tricare or any other government program; combining a manufacturer savings card with government insurance is an anti-kickback violation, not just a card restriction.

What changes when generic semaglutide arrives?

The cash-pay branded paths drop substantially. The first generic injectable semaglutide is expected in late 2026 to early 2027. Multi-source generic pricing (3+ manufacturers competing) typically lands 70 to 90 percent below branded. A patient paying $499/month for Wegovy cash today could pay $99 to $149/month for generic semaglutide in 2028. Insurance copays will fall similarly. Year-5 calculations that begin in 2026 should assume meaningful price drops in years 3 to 5.